Gabaeron is a biopharmaceutical business that develops therapeutics for neurological illnesses based on stem cells and small chemicals.
Gabaeron has raised $3.0M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Gabaeron's investors include Zhongzhi Pharmaceutical Holdings.
Gabaeron is headquartered in San Francisco, United States.
Gabaeron is a biopharmaceutical business that develops therapeutics for neurological illnesses based on stem cells and small chemicals.
Gabaeron is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gabaeron — Funding & Investors." VCBacked, December 21, 2024, https://www.vcbacked.co/company/gabaeron. Accessed October 29, 2026.
VCBacked. (2024). Gabaeron — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/gabaeron
{{cite web |title=Gabaeron — Funding & Investors |url=https://www.vcbacked.co/company/gabaeron |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated